Spyre Therapeutics Inc (SYRE)

NASDAQ
Currency in USD
14.220
+0.260(+1.86%)
Closed·
After Hours
15.070+0.880(+6.202%)
·
SYRE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
14.10514.790
52 wk Range
10.91040.490
Key Statistics
Edit
Prev. Close
13.96
Open
14.52
Day's Range
14.105-14.79
52 wk Range
10.91-40.49
Volume
618.3K
Average Vol. (3m)
704.41K
1-Year Change
-58.48%
Book Value / Share
6.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SYRE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.500
Upside
+276.23%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Spyre Therapeutics Inc Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Compare SYRE to Peers and Sector

Metrics to compare
SYRE
Peers
Sector
Relationship
P/E Ratio
−5.7x−0.4x−0.5x
PEG Ratio
−0.070.000.00
Price / Book
2.4x0.4x2.6x
Price / LTM Sales
-12.1x2.9x
Upside (Analyst Target)
305.2%308.2%57.2%
Fair Value Upside
Unlock9.4%8.9%Unlock

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 53.500
(+276.23% Upside)

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
-0.81 / -1.03
Revenue / Forecast
-- / 4.20M
EPS Revisions
Last 90 days

People Also Watch

2.850
AVIR
-0.70%
0.900
STRO
+24.14%
2.980
ACTG
+1.71%
4.930
RES
-1.40%

FAQ

What Is the Spyre Therapeutics (SYRE) Stock Price Today?

The Spyre Therapeutics stock price today is 14.22

What Stock Exchange Does Spyre Therapeutics Trade On?

Spyre Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Spyre Therapeutics?

The stock symbol for Spyre Therapeutics is "SYRE."

What Is the Spyre Therapeutics Market Cap?

As of today, Spyre Therapeutics market cap is 857.12M.

What is Spyre Therapeutics Earnings Per Share?

The Spyre Therapeutics EPS is -3.18.

What Is the Next Spyre Therapeutics Earnings Date?

Spyre Therapeutics will release its next earnings report on May 08, 2025.

From a Technical Analysis Perspective, Is SYRE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.